Bristol Myers Squibb Co. closed 1.88% below its 52-week high of $61.10, which the company reached on January 27th.

Biotech giant Bristol-Myers Squibb Company BMY is scheduled to report its fourth-quarter and full-year 2024 results on Feb. 6 ...

We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a ...

London, UK, 3 February 2025 - George Medicines, a late-stage biopharmaceutical company focused on addressing significant ...

A holistic or integrative approach to hair loss considers the hair growth cycle and hair loss from a nutritional, ...

The Union Budget 2025-26 introduces key healthcare measures, including the exemption of 36 life-saving drugs from Basic ...

Axsome Therapeutics, Inc. , a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host a virtual investor event and conference call today at ...

Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly ...

Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance ...

PHILADELPHIA – Josh Myers couldn’t have picked a worse way to venture into his uncertain future, even if the Green Bay Packers center felt he “got lucky” Sunday. “I thought I broke my leg,” Myers said ...

Chief R&D and commercial officer Najat Khan, PhD, tells GEN Edge company aims to improve design of studies, accelerate enrollment, and enhance evidence generation.